Answers are grounded in this paper and cite their sources.
Acquired resistance to temozolomide (TMZ) constitutes a formidable clinical barrier in the management of glioblastoma (GBM). GBM organoid models (GBO) that faithfully mirror the parental tumor phenotype serve as powerful research instruments to overcome the limitations in this field. We established GBOs derived from primary glioma patients and their TMZ low‐sensitivity counterparts. To unravel the intricate molecular underpinnings of this process, we performed an unbiased, integrated multi‐omics analysis encompassing epigenomic, 3D genomic, and transcriptomic profiling, coupled with dual CRISPR interference (CRISPRi) screening of TMZ‐induced enhancers (TiEns) and their cognate target genes. Our findings demonstrate that enhancer‐mediated 3D chromatin remodeling drives chemosensitivity predominantly by transcriptionally activating drug‐sensitivity‐associated genes, such as RasGRP3, VEGFA, BTN3A2 , etc. Knockdown or knockout of these genes and enhancers renders glioma cells more sensitive to TMZ, especially RasGRP3 . Our work unveils a druggable “enhancer‐chromatin‐target” signaling axis and proposes a novel combinatorial therapeutic strategy to surmount TMZ low sensitivity in GBM.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: